In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Buzz Of 2015 Pharma Dealmaking, Immuno-Oncology Is Queen Bee

Executive Summary

Big pharma keeps marching into immuno-oncology, and partnering in the field has been one of the biggest deal drivers of 2015. It’s not yet a big factor in M&A, which this year has been driven by payer pressure and generics consolidation.


Related Content

2016 Pharma Dealmaking: Waiting On The High-Value Deals
BIO: Biotech Funding Captured By Oncology
TG Therapeutics Builds A Business Model For Today
Biden’s Cancer Initiative May Intensify Industry, Government Collaboration
Biopharma Quarterly Dealmaking Statistics, Q3 2015
How To Catch The Next Wave Of Cancer Immunotherapy
Bristol Likes What It Sees In Five Prime, Invests More In CSF1R Program
Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity
After A Gargantuan Year For Pharma M&A, More To Come In 2015
Immunotherapy: Big Pharma’s Seductive Embrace


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts